<< Вернуться к списку статей журнала

Том 11 №2 2009 год - Нефрология и диализ

Безопасно ли внутривенное введение низкомолекулярного декстрана железа для коррекции анемии у больных с хронической почечной недостаточностью?

Ермоленко В.М. Михайлова Н.А. Батэрдэнэ С.

Аннотация: В сравнительном плане обобщены литературные данные о соединениях железа, используемых для в/в введения в первую очередь у больных с ХБП, находящихся на заместительной терапии. Особое внимание уделено зарегистрированному в конце 2008 г. низкомолекулярному декстрану железа (космоферу), уже успешно в течение длительного времени используемого в США и зарегистрированного кроме России еще в 50 странах. Анализ литературных данных позволил сделать однозначный вывод, что космофер по безопасности и эффективности практически не уступает зарекомендовавшему себя на российском рынке веноферу, а благодаря ряду структурных особенностей допускает одномоментное использование больших доз препарата, экономя рабочее время персонала и удешевляя лечение.

Для цитирования: Ермоленко В.М., Михайлова Н.А., Батэрдэнэ С. Безопасно ли внутривенное введение низкомолекулярного декстрана железа для коррекции анемии у больных с хронической почечной недостаточностью?. Нефрология и диализ. 2009. 11(2):109-116. doi:

Весь текст

Ключевые слова: хроническая болезнь почек, анемия, дефицит железа, соединения железа - космофер, венофер, феррлицит

Список литературы:

1. Российские Национальные Рекомендации по диагностике и лечению анемии при хронической болезни почек // Анемия. 2006. № 3. С. 3-18.
2. Фесюк А.Ф. Мордик А.И., Борисова Е.В. и др. Применение препарата «венофер» для коррекции дефицита железа у пациентов, находящихся на программном гемодиализе // Тер. архив. 2003. № 8. С. 59-61.
3. Agarwal R., Rizkala A., Kaskas M. et al. Iron sucrose causes greater proteinuria than ferric gluconate in non-dialysis chronic kidney disease // Kidney int. 2007. Vol. 72. P. 638-642.
4. Agarwal R., Vasavada N., Sachs N., Chase S. Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease // Kidney int. 2004. Vol. 65. P. 2279-2289.
5. Ahsan N. et al. Intravenous infusion of total dose iron is superior to oral iron in treatment of anemia in peritoneal dialysis patients: a single center comparative study // Am J Soc Nephrol. 1998. Vol. 9. P. 664-668.
6. Alfrey A. Toxicity of tubule fluid iron in the nephritic syndrome // Am J Physiol. 1992. Vol. 263. F637-F641.
7. Auerbach M., Ballard H., Trout R. et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label randomized trial // J Clin Oncol. 2004. Vol. 22. P. 1301-1307.
8. Auerbach M., Talib K. Low-molecular weight iron dextran and iron sucrose have similar comparative safety profiles in chronic kidney disease // Kidney int. 2008. Vol. 73. P. 528-530.
9. Auerbach M., Winchester J., Wahag A. et al. A randomized trial of three iron dextran infusion methods for anemia in EPO-treated dialysis patients // Am J Kidney Dis. 1998. Vol. 31. P. 81-86.
10. Auerbach M., Witt D., Toler W. et al. Clinical use of the total dose infusion of iron dextran // J Lab Clin Med. 1988. Vol. 111. P. 566-570.
11. Avasthi R., Aggarval M., Kataria S. Meningismus following intravenous iron dextran // J Ass Physician India. 1991. Vol. 39. P. 428-429.
12. Bailie G., Clark A., Lane Ch., Lane P. Hypersensitivity reactions and deaths associated with intravenous iron preparation // NDT. 2005. Vol. 20. Р. 1443-1449.
13. Baird I., Podmore D. Intra-muscular iron therapy in iron deficiency anemia // Lancet. 1954. Vol. 2. P. 942.
14. Barton A., Boyd A., McQuade Ch. et al. Comparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate and iron sucrose in patients undergoing hemodialysis // Pharmacotherapy. 2007. Vol. 27. P. 343-350.
15. Becker C., Macblegor R., Walker K., Jaudl J. Fatal anaphylaxis after intramuscular iron dextran // Ann Intern Med. 1966. Vol. 65. P. 745-748.
16. Bielory L. Serum sickness from iron dextran administration // Acta haematol. 1990. Vol. 83. P. 166-168.
17. Blaud P. Sur les maladies chlorotiques et sur un mode de traitment specifique dons ces affecions // Rev Med Fr Etrang. 1832. Vol. 45. P. 357-367.
18. Brain A., Walters B., Van Wyck D. Benchmarking iron dextran sensitivity: reactions requiring resuscitative medication in incident and prevalent patients // NDT. 2005. Vol. 20. P. 1438-1442.
19. Breborowicz M., Polubiuska A., Tam P. et al. Effect of iron sucrose on human peritoneal mesothelial cells // Eur J Clin Investig 2003. Vol. 33. P. 1038-1044.
20. Calvar C., Mata D., Alonso C. et al. Intravenous administration of iron gluconate during haemodialysis // NDT. 1997. Vol. 12. P. 574-575.
21. Case G. Maintaining iron balance with total dose infusion of intravenous iron dextran // ANNA J. 1998. Vol. 25. P. 65-68.
22. Charytan Ch., Levin N., Al-Saloum M. et al. Efficacy and safety of iron sucrose for iron deficiency in patients with dialysis-associated anemia: North American clinical trial // Am J Kidney Dis. 2001. Vol. 37. P. 300-307.
23. Charytan Ch., Schwenk M., Al-Saloum M. Safety of iron sucrose in hemodialysis patients intolerant to other parenteral iron products // Nephron. 2004. Vol. 96. P. 263-266.
24. Chen Y., Ho K., Xia Q. et al. Hydrogen peroxide enhances iron-induced injury in isolated heart and ventricular cardiomyocyte in rats // Mol Cell Biochem. 2002. Vol. 231. P. 61-68.
25. Chertow G., Mason Ph., Vaage-Nielsen O., Ahlenen J. On the relative safety of parenteral iron formulation // NDT. 2004. Vol. 19. P. 1571-1575.
26. Chertow G., Mason Ph., Vaage-Nilson, Ahlenen J. Update on adverse drug events associated with parenteral iron // NDT. 2006. Vol. 21. P. 378-382.
27. Cox J., King R. Valency investigations of iron dextran (Imferon) // Nature. 1965. Vol. 207. P. 1202-1203.
28. Coyne D., Adkinson F., Nissenson A. et al. Sodium ferric gluconate complex in hemodialysis patients. II. Adverse reaction in iron dextran-sensitive and dextran-tolerant patients // Kidney int. 2003. Vol. 63. P. 217-224.
29. Critchley J., Dundar Y. Adverse events associated with intravenous iron infusion (low molecular weight iron dextran and iron sucrose). A systematic review // Transfusion Altern Transfusion Med. 2007. Vol. 9. P. 8-36.
30. Crockett R., Baillod R., Lee B. et al. Maintenance of fifty patients on intermittent hemodialysis without blood transfusion // Proc EDTA. 1967. P. 17-22.
31. DeVita M., Frumkin D., Mittal S. et al. Targeting higher ferritin concentrations with intravenous iron dextran lowers erythropoietin requirement in hemodialysis patients // Clin Nephrol. 2003. Vol. 60. P. 335-340.
32. European Best Practice Guidelines for the management of anaemia in patients with chronic renal failure // NDT. 1999. Vol. 19. Suppl. 2. P. 2-46.
33. Fishbane S., Frei G., Maesaka J. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation // Am J Kidney Dis. 1995. Vol. 26. P. 41-46.
34. Flament J., Goldman M., Waterlot Y. et al. Impairment of phagocyte oxidative metabolism in hemodialyzed patients with iron overload // Clin Nephrol. 1986. Vol. 25. P. 227-230.
35. Fleming L., Hopwood D., Shepherd A., Stewart W. Hepatic iron in dialysed patients given intravenous iron dextran // J Clin Pathol. 1990. Vol. 43. P. 119-124.
36. Fletes R., Lazarus M., Gage J. et al. Suspected iron dextran-related adverse drug events in hemodialysis patients // Am J Kidney Dis. 2001. Vol. 37. P. 743-749.
37. Foulkes W., Swery C., Calam J., Hodson H. Rhabdomyolysis after intramuscular iron dextran in malabsorption // Ann Rheum Dis. 1991. Vol. 50. P. 184-186.
38. Freter S., Davidman M., Lipman M., Bercovitch D. Pulmonary edema: atypical anaphylactoid reaction to intravenous iron dextran // Am J Nephrol. 1997. Vol. 17. P. 477-479.
39. Geisser P., Baer M., Schaub E. Structure/histotoxicity relationship of parenteral iron preparations // Arzneim Forsch/Drug Res. 1992. Vol. 42. P. 1439-1452.
40. Goetisch A., Moore C., Minnich V. Observation on the effects of massive doses of iron given intravenously to patients with hypochromic anemia // Blood. 1946. Vol. 1. P. 129-142.
41. Grasso P. Sarcoma after intramuscular iron infection // Br Med J. 1973. Vol. 2. P. 667.
42. Greenberg G. Sarcoma after intramuscular iron injection // Br Med J. 1976. Vol. 3. P. 1506-1509.
43. Grune T., Sommerburg O., Siems W. Oxidativer Streβ bei Anämie // Nieren and Hochdruckkranch. 1999. Vol. 28. S24-S29.
44. Guz G., Sahinarslan A., Dhondt A. et al. Elevated cardiac troponin T in hemodialysis patients receiving more intravenous iron sucrose // Renal Fail. 2004. Vol. 26. P. 663-672.
45. Hatton R., Portales I., Finlay A. et al. Removal of iron dextran by hemodialysis: an in vitro study // Am J Kidney Dis. 1995. Vol. 26. P. 327-330.
46. Hayshi H., Yano M. Iron cytotoxicity in chronic hepatitis C // J Health Sci. 2002. Vol. 48. P. 227-231.
47. Heath C., Strauss M., Gastle W. Quantitative aspects of iron deficiency in hypochromic anemia // J Clin Investig. 1932. Vol. 11. P. 1293-1312.
48. Hoen B., Paul-Danephin A., Hestin D. et al. EPIBACDIAL: a multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients // J Am Soc Nephrol. 1998. Vol. 9. P. 869-876.
49. Humatra R., Block M., Schocket A. Intravenous iron dextran in clinical medicine // JAMA. 1980. Vol. 243. P. 1726-1731.
50. Kankaraddi V., Hoskatti C., Nadig V. et al. Comparative therapeutic study of TDI and IM injection of iron dextran complex in anemia // J Assoc Physician India. 1973. Vol. 21. P. 849-853.
51. Kapoian T., O'Mara N., Singh A. et al. Ferric gluconate reduces epoietin requirements in hemodialysis patients with elevated ferritin // J Am Soc Nephrol. 2008. Vol. 19. P. 372-379.
52. Kooistra M., Kersting S., Gosriwatana I. et al. Nontransferrin-bound iron in the plasma of haemodialysis patients after intravenous iron saccharate infusion // Eur J Clin Investig. 2002. Vol. 32. Suppl. 1. P. 36-41.
53. Locatelli F., Canand B., Eckard K. et al. Oxidative stress in end-stage renal disease: an emerging threat to patient outcome // NDT. 2003. Vol. 18. P. 1272-1280.
54. Malindres P., Sioulis A., Avgerion E. et al. Associated between intensive intravenous iron treatment and angina pectoris in hemodialysis patients // Clin Nephrol. 2006. Vol. 66. P. 312-313.
55. Manuel M., Stewart W., Clair N., Hutchinson F. Loss of iron-dextran through cuprophane membrane of disposable coil dialyser // Nephron. 1972. Vol. 9. P. 94-98.
56. McCardy P. Oral and parenteral iron therapy: a comparison // JAMA. 1965. Vol. 191. P. 155-158.
57. McCarthy J., Regnier C., Loebertmann C., Bergstralh E. Adverse events in chronic hemodialysis patients receiving intravenous iron dextran - a comparison of two products // Am J Nephrol. 2000. Vol. 20. P. 455-462.
58. Miceli M., Dong L., Grazziutti M. et al. Iron overload is a major risk factor for severe infection after autologous stem cell transplantation: a study of 367 myeloma patients // Bone Marrow Transplant. 2006. Vol. 37. P. 857-864.
59. Mircescu G., Garmata L., Capusa C., Ursea N. Intravenous iron supplementation for the treatment of anemia in pre-dialyzed chronic renal failure patients // NDT. 2006. Vol. 21. P. 120-124.
60. Mircescu G., Garneata L., Capusa C., Ursea N. Intravenous iron supplementation for the treatment of anaemia in pre-dialyzed chronic renal failure patients // NDT. 2006. Vol. 21. P. 120-124.
61. Moniem K., Bhandari S. Tolerability and efficacy of parenteral iron therapy in hemodialysis patients: a comparison of preparations // Transfusion Altern Transfusion Med. 2007. Vol. 9. P. 37-42.
62. Moniem K., Bhandari S. Tolerability and efficacy of parenteral iron therapy in haemodialysis patients // J Am Soc Nephrol. 2003. Vol. 14. 705A.
63. Mossey R., Sondheimer J. Listeriosis in patients with long term hemodialysis and transfusional iron overload // Am J Med. 1985. Vol. 79. P. 397-400.
64. Mudge H., Weiner I. Agents affecting volume and composition of body fluids / In: The Pharmacological Basis of Therapeutics. New York, Pergamon Press, 1990. P. 682-707.
65. Müller A. Arzneim-Forsch Drug Res, 1974. Vol. 24. P. 880.
66. Nanas J. Etiology of anemia in patients with advanced heart failure // J Am Coll Cardiol. 2006. Vol. 48. P. 2485-2489.
67. Nissim J. Intravenous administration of iron // Lancet. 1947. Vol. 1. P. 49-51.
68. Oh V. Iron dextran and systemic lupus erythematosus // Brit J Med. 1992. Vol. 305. P. 1000.
69. Okonko D., Grzeslo A., Witkowski T. et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and non-anemic patients with symptomatic chronic heart failure and iron deficiency. FERRIC-HF a randomized controlled observer-blinded trial // J Am Coll Cardiol. 2008. P. 103-112.
70. Patruta S., Edlinger R., Sunder-Plassman G., Hörl W. Neutrophil impairment associated with iron therapy in hemodialysis patients with functional iron deficiency // J Am Soc Nephrol. 1998. Vol. 9. P. 655-663.
71. Peck S., Piccoli D., Baldassano R. Safety and efficacy of iron dextran infusions in children with inflammatory bowel disease and iron deficiency anemia // J Pediatr Gastroenterol and Nutrition. 1998. Vol. 27. P. 487.
72. Revised European Best Practice Guidelines for the management of anaemia in patients with chronic renal failure // NDT. 2004. Vol. 19. Suppl. 2. P. 2-46.
73. Rooyakkers T., Stroes E., Kooistra M. et al. Ferric saccharate induces oxygen radical stress and endothelial dysfunction in vivo // Eur J Clin Investig. 2002. Vol. 32. Suppl. 1. P. 9-16.
74. Saltissi D., Sauvage D., Westhuyzen J. Comparative response to single or divided doses of parenteral iron for functional deficiency in hemodialysis patients receiving erythropoietin (EPO) // Clin Nephrol. 1998. Vol. 49. P. 45-48.
75. Sanai T., Oochi N., Okada M. et al. Effect of saccharated ferric oxide and iron dextran on the metabolism of phosphorus in rats // J Lab Clin Med. 2005. Vol. 146. P. 25-29.
76. Sane R., Baribeault D., Rosenberg C. Safe administration of iron sucrose in a patient with a previous hypersensitivity reaction to ferric gluconate // Pharmacotherapy. 2007. Vol. 27. P. 613-615.
77. Sargent J., Acchiardo S. Iron requirements in hemodialysis // Blood Purif. 2004. Vol. 22. P. 112-123.
78. Sav T., Tokgoz B., Sipahioglu M. et al. Is there a difference between the allergic potencies of the iron sucrose and low molecular weight iron dextran? // Renal failure. 2007. Vol. 29. P. 423-426.
79. Schaefer R. Safety of intravenous iron dextran in patients receiving haemodialysis. Erythropoiesis: new dimensions in the treatment anaemia //NDT. 1997. Vol. 8. P. 49-50.
80. Schiller B., Doss S., De Cock E. et al. Activity based cost analysis of in center anemia treatment in hemodialysis patients. // NKF 2007 Spring Clinical Meeting. Orlando, 2007. abstr. 248.
81. Schwenk M., Blaustein D. Rapid, high-dose intravenous iron sucrose therapy in 2 Jehovah’s Witness patient with severe anemia, iron deficiency and chronic kidney disease // Clin Nephrol. 2004. Vol. 62. P. 116-120.
82. Senger J., Weiss R. Hematologic and erythropoietin responses to iron dextran in the hemodialysis environment // ANNA J. 1996. Vol. 23. P. 319-323.
83. Sepandj F., Jindal K., West M., Hirschu D. Economic appraisal of maintenance parenteral iron administration in treatment of anaemia in chronic haemodialysis patients // NDT. 1996. Vol. 11. P. 319-322.
84. Sharma J. A prospective, partially randomized study of pregnancy outcomes and hematologic responses to oral and intramuscular iron treatment in moderately anemic pregnant women // Am J Clin Nutr. 2004. Vol. 79. P. 116-122.
85. Siems W., Carinccio F., Grune T. et al. Elevated concentration of cardiotoxic lipid peroxidation products in chronic renal failure in relation to severity of renal anemia // Clin Nephrol. 2002. Vol. 58. Suppl. 1. P. 20-25.
86. Silverberg D., Blum M., Aglaria Z. et al. The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period // Clin Nephrol. 2001. Vol. 55. P. 212-219.
87. Singh A., Patel T., Hertel J. et al. Safety of ferumoxytol in patients with anemia and CKD // Am J Kidney Dis. 2008. Vol. 52. P. 907-915.
88. Stockman R. The treatments of chlorosis with iron and some other drugs // Brit Med J. 1893. Vol. 1. P. 881-885.
89. Strickland I., Chaput de Saintouge et al. The therapeutic equivalence of oral and intravenous iron in renal dialysis patients // Clin Nephrol. 1977. Vol. 7. P. 55-57.
90. Van Wick D., Cavallo G., Spinowitz B. et al. Safety and efficacy of iron sucrose in patients sensitive to iron dextran: North Amerrican clinical trial // Am J Kidney Dis. 2000. Vol. 36. P. 88-97.
91. Van Wick D., Roppolo M., Martinez C. et al. A randomized controlled trial comparing IV iron sucrose to oral iron in anemic patients with non-dialysis-dependent CKD // Kidney int. 2005. Vol. 68. P. 2846-2856.
92. Van Wyek D., Cavallo G., Spinowitz B. et al. Safety and efficacy of iron sucrose in patients sensitive to iron dextran. North American Clinical Trial // Am J Kidney Dis. 2000. Vol. 36. P. 88-97.
93. Wallenstein R. Intravenous iron-dextran complex // Blood. 1998. Vol. 32. P. 690-695.
94. Waterlot Y., Cantinieaux B., Harcia-Muller Ch. et al. Impaired phagocytic activity of neutrophils in patients receiving haemodialysis: the critical role of iron overload // Brit Med J. 1985. Vol. 291. P. 501-504.
95. Wood J. The Metabolism of iron-dextran given as a total-dose infusion to iron deficient jamaican subjects // Brit J Haematol. 1968. Vol. 14. P. 119-129.
96. Yee J., Besarab A. Iron sucrose: the oldest iron therapy becomes news // Am J Kidney Dis. 2002. Vol. 40. P. 1111-1121.
97. Zager R., Johnson A., Hanson Sh. et al. Parenteral iron formulations: a comparative toxicologic analysis and mechanisms of cells injury // Am J Kidney Dis. 2002. Vol. 40. P. 90-103.
98. Zager R., Johnson A., Hanson Sh. Parenteral iron exacerbates experimental sepsis // Kidney int. 2004. Vol. 65. P. 2108-2112.
99. Zager R., Johnson A., Hanson Sh. Parenteral iron nephrotoxicity: potential mechanisms // Kidney int. 2004. Vol. 66. P. 144-156.
100. Zager R., Johnson A., Hanson Sh., Zund S. Parenteral compounds sensitize mice to injury-initiated TNF alfa release // Am J Physiol. 2005. Vol. 288. F295-F297.
101. Zeligson A. Anaphylactic shock after intravenous Imferon // Harefuah. 1970. Vol. 79. P. 283.
102. Zhao Z., Cheng G., Xiao J. et al. Intravenous infusion of total dose iron dextran in treatment anemia for peritoneal dialysis patients // Chin J New Drugs Clin Rem. 2005. Vol. 9. P. 750-752.
103. Zheng H., Cable R., Spencer B. et al. Iron stores and vascular function in voluntary blood donors // Arterioscler Tromb Vasc Biol. 2005. Vol. 25. P. 1577-1583.
104. Zipt R. Fatal anaphylaxis after intravenous iron dextran // J Forensic Sci Int. 1976. Vol. 20. P. 326.

Другие статьи по теме

• Кардиоренальный анемический синдром у больных пожилого возраста
• Использование венофера для лечения анемии при хронической почечной недостаточности
• Морфофункциональные свойства эритроцитов у больных в терминальной стадии хронической почечной недостаточности, получающих заместительное лечение программным гемодиализом и эритропоэтином
• Анемия у беременных женщин с хронической болезнью почек